MCK Price Prediction Next Week
MCK Stock Price Prediction and Recommendation
Technical Analysis:
- Current Price: $644.22 (as of 2025-03-07)
- RSI (6): 73.85 (Overbought range, indicating potential pullback)
- MACD (12,26): 12.72 (Bullish crossover, indicating upward momentum)
- Fibonacci Levels: Resistance at $649.68 (R1) and $662.74 (R2)
News and Fundamental Analysis:
- Strong Buy Rating: Analysts maintain a "Strong Buy" rating with a mean price target of $677.80.
- Recent Acquisitions: Strategic acquisitions in oncology and specialty services expected to drive growth.
- Earnings Performance: Q3 earnings were weaker than expected, but the company raised its FY25 EPS guidance.
Price Prediction:
- Target Price: $652 (next trading week)
- Recommendation: BUY with a stop-loss at $636
MCK Similar Chart Price Prediction
The price of MCK is predicted to go up -27.81%, based on the high correlation periods with DRUG. The similarity of these two price pattern on the periods is 97.05%.
MCK
DRUG
Down: -27.81%Similarity: 97.05%
MCK Revenue Forecast
MCK EPS Forecast
MCK FAQs
What is MCK revenue forecast for next quarter？
What is MCK eps forecast for next quarter？
MCK VS S&P500
McKesson distributes pharmaceutical products to nearly one third of the industry, leading to substantial negotiation leverage with generic drug manufacturers.
Direct-to-store model (delivering drugs directly to each retailer's stores) of distributors are increasingly becoming more popular among retailers (represents 93% of sales in 2017, up from 74% in 2007), solidifying McKesson's role in the supply chain.
Technology advancements continue to improve McKesson's performance and present new opportunities for wholesalers.
MCK Analyst's Forecast
Daniel Grosslight
Citigroup
Strong Buy
2025-01-10
Price Target
$713 → $677
Upside
+16.38%
Citi lowered the firm's price target on McKesson to $677 from $713 and keeps a Buy rating on the shares as part of a 2025 outcook for the health technology and distribution group. The firm says that while 2024 was another difficult year for health tech stocks, rather than being driven by deteriorating fundamentals, much of the selloff was due to continued multiple compression, which signals "we have likely reached a valuation floor." Looking ahead to 2025, Citi is "cautiously optimistic" on the health tech space, saying there seems to be a bit of a post-election risk bid, acquisition activity has accelerated, and expectations have been sufficiently reset. Citi names Health Catalyst (HCAT) its top health tech pick and Cencora (COR) its top distribution pick.
Erin Wright
Morgan Stanley
Buy
2024-12-17
Price Target
$612 → $642
Upside
+14.08%
Stephen Baxter
Wells Fargo
Hold
2024-12-13
Price Target
$535 → $641
Upside
+11.24%
